Conference call and webcast to be held at 8:30 a.m. ET
NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ — Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company, is set to unveil topline results from its Phase 2b CORAL trial of Haduvio, its investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Investors and analysts should mark their calendars, as the company will host a conference call and live webcast tomorrow, Monday, June 2nd, 2025, at 8:30 a.m. ET to discuss the findings.
The call offers a crucial opportunity to gain insight into the potential of Haduvio (oral nalbuphine ER), which is also being developed for refractory chronic cough (RCC). The live webcast, including accompanying audio and presentation slides, can be accessed via a link here. For those preferring to dial in, the domestic number is (877) 870 4263, and the international number is (412) 317 0790. No access code is required. A replay of the webcast will be available on the company’s website for 30 days post-event.
**The IPF Chronic Cough Conundrum**
Chronic cough represents a significant challenge in IPF patients, affecting up to 85% of this population. With approximately 140,000 patients in the U.S. battling IPF, the impact is considerable, with some patients enduring up to 1,500 coughs daily. This relentless cycle not only worsens the disease but also elevates the risk of progression, complications, and the need for a lung transplant. Beyond the physical toll, it drastically impacts patients’ social, physical, and psychological well-being. Currently, the lack of approved therapies for IPF chronic cough leaves a void that Trevi Therapeutics hopes to fill.
**Haduvio: A New Hope?**
Trevi Therapeutics is positioning Haduvio as a potential breakthrough. The drug acts on the cough reflex arc at both a central and peripheral level, targeting the opioid receptors crucial in controlling chronic cough. So far, results from the company’s clinical trials showed a statistically-significant reduction in cough frequency for patients with IPF chronic cough and those with RCC.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority, and investors and analysts will be keen to see the data from the CORAL trial, which could shape the future of this burgeoning therapeutic.
For further details, visit www.TreviTherapeutics.com, or follow Trevi on X and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-host-conference-call-and-webcast-on-june-2nd-to-share-topline-results-from-the-phase-2b-coral-trial-of-haduvio-in-patients-with-idiopathic-pulmonary-fibrosis-chronic-cough-302470171.html
SOURCE Trevi Therapeutics, Inc.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/1492.html
